EUVIMEDEUVIMED entdecken
Crossref

Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes

Adrien Joseph iD, Stéphanie Harel, Laurent Mesnard, Cédric Rafat, Silène Knapp, Anne Rumpler, Carole Philipponnet iD, Christophe Barba, Jean-Michel Rebibou, David Buob, Alexandre Hertig, Jacques Vargaftig und 6 weitere

Nephrology Dialysis Transplantation · 2024

DOI: 10.1093/ndt/gfae096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Adrien Joseph und 17 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine intensive réanimation, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Oligopeptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Plan for Rare Diseases of the French Ministry of Health, Direction Générale de l'offre de Soins, Direction Générale de l’offre de Soins.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carfilzomib, a new proteasome inhibitor indicated for patients with relapsed/refractory myeloma, has been associated with cases of thrombotic microangiopathy (CFZ-TMA). The role of variants in the complement alternative pathway and therapeutic potential of complement blockade with eculizumab remain to be determined.

Methods

We report 37 cases of CFZ-TMA recorded in the French reference center for TMA with their clinical characteristics, genetic analysis and outcome according to treatments.

Results

A trigger was identified in more than half of cases, including eight influenza and five severe acute respiratory syndrome coronavirus-2 cases. All patients presented with acute kidney injury (AKI) [KDIGO stage 3 in 31 (84%) patients] while neurological (n = 13, 36%) and cardiac (n = 7, 19%) damage were less frequent. ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I repeats-13) and complement activity were normal (n = 28 and 18 patients tested) and no pathogenic variant in the alternative complement pathway was found in 7 patients tested. TMA resolved in most (n = 34, 94%) patients but 12 (44%) still displayed stage 3 AKI at discharge. Nineteen (51%) patients were treated with therapeutic plasma exchange, 14 (38%) patients received corticosteroids and 18 (50%) were treated with eculizumab. However, none of these treatments demonstrated a significant impact on outcomes.

Conclusion

This study is the largest case series of CFZ-TMA since its approval in 2012. Patients present with severe AKI and experience frequent sequelae. Complement variants and blockade therapy do not seem to play a role in the pathophysiology and prognosis of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesOligopeptidesHumansMaleFemaleMiddle AgedAgedAcute Kidney InjuryCOVID-19Antibodies, Monoclonal, HumanizedMultiple MyelomaAdultProteasome InhibitorsSARS-CoV-2Retrospective StudiesAged, 80 and over

Stichwörter der Autor:innen

carfilzomibcomplementeculizumabmyelomathrombotic microangiopathy

Substanzen

carfilzomibOligopeptideseculizumabAntibodies, Monoclonal, HumanizedProteasome Inhibitors

Autor:innen und Institutionen

  • Service de Médecine intensive réanimation, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
  • Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), Assistance Publique des Hôpitaux de Paris, Paris, France.
  • Service d'immuno-hématologie, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
  • Soins Intensifs Néphrologiques et Rein Aigu, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, Paris, France.
  • UMR_S1155, INSERM, Sorbonne Université, Paris, France.
  • Service d'hématologie, Centre Hospitalier Universitaire de Besançon, Besançon, France.

ORCID-Profile: Adrien Joseph, Carole Philipponnet

Förderung

  • National Plan for Rare Diseases of the French Ministry of Health
  • Direction Générale de l'offre de Soins
  • Direction Générale de l’offre de Soins

Zitieren

APA

Joseph, A., Harel, S., Mesnard, L., Rafat, C., Knapp, S., Rumpler, A., Philipponnet, C., Barba, C., Rebibou, J. M., Buob, D., Hertig, A., Vargaftig, J., Halimi, J. M., Arnulf, B., Bretaud, A. S., Joly, B., Grangé, S., & Coppo, P. (2024). Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae096

Vancouver

Joseph A, Harel S, Mesnard L, Rafat C, Knapp S, Rumpler A, et al. Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae096

BibTeX
@article{Joseph2024,
  author = {Joseph, Adrien and Harel, Stéphanie and Mesnard, Laurent and Rafat, Cédric and Knapp, Silène and Rumpler, Anne and Philipponnet, Carole and Barba, Christophe and Rebibou, Jean-Michel and Buob, David and Hertig, Alexandre and Vargaftig, Jacques and Halimi, Jean-Michel and Arnulf, Bertrand and Bretaud, Anne-Sophie and Joly, Bérangère and Grangé, Steven and Coppo, Paul},
  title = {Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  doi = {10.1093/ndt/gfae096}
}
Kostenlos starten →